Fenghuang Zhan
Concepts (549)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 132 | 2024 | 2929 | 9.780 |
Why?
| Drug Resistance, Neoplasm | 25 | 2020 | 308 | 3.280 |
Why?
| Gene Expression Regulation, Neoplastic | 51 | 2022 | 828 | 3.190 |
Why?
| Gene Expression Profiling | 43 | 2023 | 1032 | 2.860 |
Why?
| Cell Proliferation | 25 | 2022 | 1007 | 2.270 |
Why?
| Antineoplastic Agents | 29 | 2020 | 1171 | 2.180 |
Why?
| Plasma Cells | 22 | 2024 | 223 | 2.030 |
Why?
| Cell Line, Tumor | 44 | 2024 | 1403 | 1.930 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 7 | 2023 | 103 | 1.740 |
Why?
| Neoplastic Stem Cells | 7 | 2020 | 103 | 1.710 |
Why?
| Pyrazines | 19 | 2023 | 187 | 1.620 |
Why?
| Paraproteinemias | 9 | 2024 | 72 | 1.480 |
Why?
| Lymphoma, B-Cell | 5 | 2021 | 63 | 1.450 |
Why?
| Mice | 45 | 2024 | 5739 | 1.420 |
Why?
| Boronic Acids | 17 | 2014 | 182 | 1.400 |
Why?
| Apoptosis | 17 | 2022 | 1101 | 1.400 |
Why?
| Bone Resorption | 6 | 2024 | 304 | 1.390 |
Why?
| Humans | 151 | 2024 | 49974 | 1.300 |
Why?
| Neoplasm Proteins | 7 | 2021 | 322 | 1.220 |
Why?
| Prognosis | 36 | 2024 | 1942 | 1.170 |
Why?
| Osteolysis | 4 | 2022 | 75 | 1.150 |
Why?
| Animals | 54 | 2024 | 13187 | 1.140 |
Why?
| B-Lymphocytes | 8 | 2021 | 170 | 1.120 |
Why?
| Cell Cycle Proteins | 4 | 2023 | 166 | 1.060 |
Why?
| T-Lymphocytes | 8 | 2024 | 338 | 1.020 |
Why?
| Hematopoietic Stem Cell Transplantation | 6 | 2024 | 565 | 1.010 |
Why?
| Ubiquitination | 3 | 2021 | 43 | 0.970 |
Why?
| Proteasome Inhibitors | 7 | 2020 | 104 | 0.950 |
Why?
| Signal Transduction | 21 | 2023 | 1618 | 0.900 |
Why?
| Proteasome Endopeptidase Complex | 4 | 2018 | 114 | 0.850 |
Why?
| MicroRNAs | 7 | 2022 | 353 | 0.850 |
Why?
| Antigens, CD | 8 | 2024 | 219 | 0.780 |
Why?
| Carrier Proteins | 3 | 2017 | 304 | 0.690 |
Why?
| CDC2-CDC28 Kinases | 3 | 2015 | 12 | 0.680 |
Why?
| Cation Transport Proteins | 2 | 2019 | 27 | 0.670 |
Why?
| Ubiquitins | 2 | 2016 | 39 | 0.650 |
Why?
| Up-Regulation | 6 | 2020 | 452 | 0.650 |
Why?
| Disease Progression | 17 | 2023 | 825 | 0.640 |
Why?
| Cyclin-Dependent Kinases | 2 | 2010 | 28 | 0.640 |
Why?
| Glycolysis | 3 | 2022 | 70 | 0.640 |
Why?
| Mice, Inbred NOD | 5 | 2020 | 96 | 0.640 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2014 | 411 | 0.630 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2018 | 40 | 0.630 |
Why?
| Proto-Oncogene Proteins c-akt | 5 | 2023 | 157 | 0.610 |
Why?
| Chromosome Aberrations | 6 | 2023 | 297 | 0.610 |
Why?
| Cell Differentiation | 9 | 2023 | 651 | 0.600 |
Why?
| Iron | 2 | 2017 | 122 | 0.600 |
Why?
| Pyrimidines | 3 | 2015 | 192 | 0.590 |
Why?
| STAT3 Transcription Factor | 4 | 2016 | 81 | 0.590 |
Why?
| Cell Survival | 10 | 2020 | 600 | 0.580 |
Why?
| Pyruvate Kinase | 1 | 2017 | 7 | 0.580 |
Why?
| Ascorbic Acid | 1 | 2017 | 24 | 0.580 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 989 | 0.560 |
Why?
| RNA Splicing | 1 | 2017 | 37 | 0.560 |
Why?
| Protein-Tyrosine Kinases | 2 | 2015 | 95 | 0.530 |
Why?
| Down-Regulation | 9 | 2019 | 348 | 0.520 |
Why?
| Cyclopentanes | 1 | 2015 | 10 | 0.520 |
Why?
| Transplantation, Autologous | 5 | 2024 | 466 | 0.510 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 67 | 0.510 |
Why?
| Thalidomide | 10 | 2023 | 377 | 0.500 |
Why?
| Aldehyde Dehydrogenase | 1 | 2014 | 26 | 0.500 |
Why?
| Osteoclasts | 7 | 2023 | 425 | 0.490 |
Why?
| Dexamethasone | 7 | 2024 | 430 | 0.480 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2020 | 18 | 0.480 |
Why?
| Hematologic Neoplasms | 1 | 2015 | 99 | 0.450 |
Why?
| Receptors, Retinoic Acid | 2 | 2013 | 23 | 0.450 |
Why?
| Models, Biological | 5 | 2018 | 727 | 0.450 |
Why?
| Cystatin M | 2 | 2024 | 20 | 0.450 |
Why?
| RNA, Messenger | 13 | 2021 | 1105 | 0.440 |
Why?
| Tumor Microenvironment | 5 | 2024 | 212 | 0.440 |
Why?
| B-Cell Maturation Antigen | 2 | 2024 | 90 | 0.430 |
Why?
| Flow Cytometry | 8 | 2018 | 476 | 0.430 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 151 | 0.420 |
Why?
| Glucuronidase | 4 | 2018 | 46 | 0.420 |
Why?
| Female | 43 | 2024 | 26472 | 0.410 |
Why?
| Antibodies, Bispecific | 2 | 2023 | 60 | 0.400 |
Why?
| Predictive Value of Tests | 5 | 2016 | 903 | 0.400 |
Why?
| Male | 33 | 2024 | 25241 | 0.390 |
Why?
| Mice, Transgenic | 6 | 2021 | 555 | 0.380 |
Why?
| Syndecan-1 | 6 | 2017 | 72 | 0.380 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 6 | 0.380 |
Why?
| Arsenicals | 1 | 2010 | 14 | 0.380 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 20 | 0.380 |
Why?
| Oxides | 1 | 2010 | 18 | 0.370 |
Why?
| Janus Kinase 1 | 1 | 2010 | 17 | 0.360 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 12 | 2015 | 595 | 0.360 |
Why?
| Proto-Oncogene Proteins c-jun | 2 | 2009 | 75 | 0.360 |
Why?
| MAP Kinase Kinase 1 | 1 | 2010 | 23 | 0.360 |
Why?
| Immunotherapy, Adoptive | 2 | 2024 | 156 | 0.360 |
Why?
| Killer Cells, Natural | 4 | 2015 | 95 | 0.350 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 83 | 0.350 |
Why?
| DNA-Binding Proteins | 4 | 2021 | 427 | 0.350 |
Why?
| Early Growth Response Protein 1 | 1 | 2009 | 35 | 0.340 |
Why?
| Transcription Factors | 6 | 2022 | 561 | 0.330 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 105 | 0.330 |
Why?
| Oligopeptides | 3 | 2015 | 89 | 0.330 |
Why?
| Tretinoin | 1 | 2009 | 53 | 0.330 |
Why?
| Xenograft Model Antitumor Assays | 7 | 2019 | 211 | 0.320 |
Why?
| Osteogenesis | 5 | 2023 | 352 | 0.310 |
Why?
| NF-kappa B | 3 | 2018 | 314 | 0.310 |
Why?
| Genes, Neoplasm | 1 | 2008 | 30 | 0.310 |
Why?
| Tumor Cells, Cultured | 6 | 2020 | 465 | 0.310 |
Why?
| Antibodies | 3 | 2024 | 154 | 0.310 |
Why?
| Aged | 24 | 2024 | 9310 | 0.310 |
Why?
| Microarray Analysis | 3 | 2018 | 73 | 0.300 |
Why?
| Chromosomes, Human, Pair 1 | 4 | 2023 | 93 | 0.290 |
Why?
| Immunologic Factors | 5 | 2015 | 114 | 0.290 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 2 | 0.290 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2008 | 202 | 0.290 |
Why?
| Interleukin-6 | 3 | 2019 | 264 | 0.290 |
Why?
| Neoplasms | 2 | 2015 | 1235 | 0.290 |
Why?
| Neoplasms, Plasma Cell | 2 | 2023 | 37 | 0.290 |
Why?
| Pyrazoles | 2 | 2020 | 113 | 0.280 |
Why?
| Small Molecule Libraries | 2 | 2019 | 68 | 0.280 |
Why?
| Mice, SCID | 9 | 2018 | 175 | 0.270 |
Why?
| Risk Factors | 11 | 2018 | 3613 | 0.260 |
Why?
| Middle Aged | 23 | 2024 | 12069 | 0.250 |
Why?
| Genomics | 2 | 2023 | 286 | 0.250 |
Why?
| Survival Rate | 8 | 2020 | 894 | 0.250 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 391 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.240 |
Why?
| Bone Diseases | 4 | 2016 | 99 | 0.240 |
Why?
| Bone Marrow | 7 | 2024 | 362 | 0.240 |
Why?
| Receptors, LDL | 1 | 2024 | 66 | 0.230 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.230 |
Why?
| TNF Receptor-Associated Factor 3 | 2 | 2022 | 13 | 0.230 |
Why?
| Propionates | 1 | 2024 | 24 | 0.230 |
Why?
| Hydroxybenzoates | 1 | 2024 | 25 | 0.230 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.230 |
Why?
| X-Ray Microtomography | 1 | 2024 | 77 | 0.230 |
Why?
| Histocompatibility Antigens Class I | 2 | 2015 | 44 | 0.230 |
Why?
| Antigens, CD19 | 3 | 2018 | 24 | 0.230 |
Why?
| Cholesterol | 1 | 2024 | 146 | 0.230 |
Why?
| Melphalan | 3 | 2023 | 174 | 0.230 |
Why?
| Bone Marrow Cells | 4 | 2015 | 191 | 0.230 |
Why?
| Neoplasms, Second Primary | 1 | 2024 | 78 | 0.230 |
Why?
| Membrane Glycoproteins | 6 | 2009 | 240 | 0.220 |
Why?
| Genes, myc | 3 | 2019 | 40 | 0.220 |
Why?
| Intercellular Signaling Peptides and Proteins | 4 | 2007 | 104 | 0.220 |
Why?
| Lymphoma | 1 | 2024 | 66 | 0.220 |
Why?
| Bone Diseases, Metabolic | 1 | 2024 | 74 | 0.220 |
Why?
| Homeostasis | 1 | 2024 | 200 | 0.220 |
Why?
| Cluster Analysis | 5 | 2009 | 235 | 0.220 |
Why?
| Gene Knockdown Techniques | 3 | 2018 | 106 | 0.220 |
Why?
| Bone and Bones | 2 | 2021 | 469 | 0.220 |
Why?
| NM23 Nucleoside Diphosphate Kinases | 1 | 2022 | 4 | 0.210 |
Why?
| Recurrence | 7 | 2018 | 652 | 0.210 |
Why?
| Protein Binding | 2 | 2018 | 660 | 0.210 |
Why?
| Neutropenia | 1 | 2023 | 116 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 6 | 2016 | 549 | 0.210 |
Why?
| Periodontitis | 1 | 2022 | 10 | 0.210 |
Why?
| Phenols | 1 | 2024 | 113 | 0.210 |
Why?
| Case-Control Studies | 8 | 2020 | 1131 | 0.210 |
Why?
| Reactive Oxygen Species | 4 | 2017 | 408 | 0.210 |
Why?
| Antibodies, Monoclonal | 3 | 2013 | 459 | 0.210 |
Why?
| In Situ Hybridization, Fluorescence | 5 | 2023 | 259 | 0.200 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 154 | 0.200 |
Why?
| Protein Stability | 2 | 2020 | 43 | 0.200 |
Why?
| Osteoporosis | 1 | 2023 | 146 | 0.200 |
Why?
| Adult | 20 | 2024 | 13236 | 0.200 |
Why?
| Kaplan-Meier Estimate | 5 | 2016 | 466 | 0.200 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 105 | 0.200 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 1 | 0.190 |
Why?
| Nuclear Factor 90 Proteins | 1 | 2021 | 1 | 0.190 |
Why?
| Ubiquitin-Protein Ligases | 2 | 2020 | 92 | 0.190 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.190 |
Why?
| Venous Thromboembolism | 3 | 2011 | 68 | 0.190 |
Why?
| Oxidative Stress | 4 | 2016 | 770 | 0.190 |
Why?
| Phenylpropionates | 1 | 2021 | 13 | 0.190 |
Why?
| Hippurates | 1 | 2021 | 11 | 0.190 |
Why?
| Gene Expression | 4 | 2017 | 609 | 0.190 |
Why?
| Proteolysis | 3 | 2017 | 94 | 0.190 |
Why?
| Cell Cycle | 4 | 2010 | 231 | 0.190 |
Why?
| Bone Neoplasms | 2 | 2015 | 179 | 0.190 |
Why?
| Membrane Proteins | 3 | 2017 | 341 | 0.190 |
Why?
| Colorectal Neoplasms | 2 | 2022 | 236 | 0.190 |
Why?
| Colonic Neoplasms | 1 | 2022 | 161 | 0.190 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 197 | 0.190 |
Why?
| Protease Inhibitors | 3 | 2011 | 58 | 0.180 |
Why?
| Treatment Outcome | 12 | 2020 | 5141 | 0.180 |
Why?
| Cell Movement | 2 | 2015 | 247 | 0.180 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2021 | 53 | 0.180 |
Why?
| Antigens, CD20 | 2 | 2014 | 6 | 0.180 |
Why?
| Neoplasm Metastasis | 4 | 2015 | 231 | 0.180 |
Why?
| Retrospective Studies | 7 | 2024 | 6108 | 0.180 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 55 | 0.180 |
Why?
| Time Factors | 8 | 2021 | 2903 | 0.180 |
Why?
| Disease-Free Survival | 7 | 2016 | 454 | 0.180 |
Why?
| Evolution, Molecular | 1 | 2021 | 99 | 0.180 |
Why?
| Chromosomal Instability | 3 | 2021 | 16 | 0.180 |
Why?
| Cytotoxicity, Immunologic | 4 | 2015 | 54 | 0.180 |
Why?
| Clinical Trials as Topic | 1 | 2022 | 461 | 0.170 |
Why?
| Tumor Suppressor Proteins | 2 | 2019 | 128 | 0.170 |
Why?
| Neoplasm Recurrence, Local | 1 | 2024 | 614 | 0.170 |
Why?
| DNA, Single-Stranded | 1 | 2020 | 87 | 0.170 |
Why?
| NF-E2-Related Factor 2 | 1 | 2019 | 41 | 0.170 |
Why?
| Oncogene Proteins | 1 | 2019 | 17 | 0.170 |
Why?
| Mitosis | 3 | 2015 | 91 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 257 | 0.170 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2019 | 24 | 0.160 |
Why?
| Transplantation, Heterologous | 2 | 2017 | 74 | 0.160 |
Why?
| rab GTP-Binding Proteins | 1 | 2019 | 35 | 0.160 |
Why?
| Receptors, Interleukin-6 | 1 | 2018 | 22 | 0.160 |
Why?
| Proto-Oncogene Proteins c-myc | 2 | 2017 | 50 | 0.160 |
Why?
| Drug Tolerance | 1 | 2018 | 60 | 0.160 |
Why?
| Pyridines | 1 | 2019 | 130 | 0.160 |
Why?
| Neovascularization, Pathologic | 3 | 2009 | 161 | 0.160 |
Why?
| Blotting, Western | 3 | 2015 | 601 | 0.160 |
Why?
| Lung Neoplasms | 1 | 2024 | 606 | 0.150 |
Why?
| Drug Therapy, Combination | 2 | 2017 | 377 | 0.150 |
Why?
| beta Catenin | 2 | 2015 | 102 | 0.150 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2017 | 4 | 0.150 |
Why?
| Mice, Knockout | 4 | 2023 | 841 | 0.150 |
Why?
| Hydroxamic Acids | 2 | 2014 | 38 | 0.150 |
Why?
| Aerobiosis | 1 | 2017 | 14 | 0.140 |
Why?
| Microfilament Proteins | 1 | 2017 | 43 | 0.140 |
Why?
| Thyroid Hormones | 1 | 2017 | 18 | 0.140 |
Why?
| Onium Compounds | 1 | 2016 | 13 | 0.140 |
Why?
| Calcium-Binding Proteins | 1 | 2017 | 54 | 0.140 |
Why?
| Organophosphorus Compounds | 1 | 2016 | 15 | 0.140 |
Why?
| Deoxyglucose | 1 | 2016 | 36 | 0.140 |
Why?
| Histone Deacetylase Inhibitors | 2 | 2014 | 53 | 0.140 |
Why?
| Survival Analysis | 6 | 2020 | 653 | 0.140 |
Why?
| Inhibitor of Apoptosis Proteins | 3 | 2015 | 20 | 0.140 |
Why?
| Syndecans | 3 | 2006 | 34 | 0.140 |
Why?
| Gene Deletion | 2 | 2008 | 266 | 0.140 |
Why?
| Pancreatic Neoplasms | 1 | 2019 | 208 | 0.140 |
Why?
| Aged, 80 and over | 7 | 2021 | 3129 | 0.140 |
Why?
| RNA Interference | 2 | 2015 | 179 | 0.140 |
Why?
| Ribosomal Proteins | 1 | 2016 | 25 | 0.130 |
Why?
| Cell Death | 1 | 2016 | 181 | 0.130 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 43 | 0.130 |
Why?
| Proteoglycans | 3 | 2006 | 80 | 0.130 |
Why?
| Macrophages | 2 | 2022 | 363 | 0.130 |
Why?
| Proto-Oncogene Proteins | 2 | 2009 | 149 | 0.130 |
Why?
| Oncolytic Virotherapy | 1 | 2015 | 16 | 0.130 |
Why?
| Gene Dosage | 2 | 2013 | 78 | 0.130 |
Why?
| Cell Adhesion Molecules | 1 | 2015 | 88 | 0.130 |
Why?
| Polysaccharides | 1 | 2015 | 50 | 0.130 |
Why?
| Receptors, Transferrin | 1 | 2015 | 16 | 0.130 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 44 | 0.130 |
Why?
| Side-Population Cells | 1 | 2015 | 3 | 0.130 |
Why?
| Lentivirus | 1 | 2015 | 16 | 0.130 |
Why?
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.130 |
Why?
| Serine Endopeptidases | 2 | 2006 | 52 | 0.130 |
Why?
| Receptors, Cell Surface | 1 | 2015 | 122 | 0.120 |
Why?
| Adenine | 1 | 2015 | 32 | 0.120 |
Why?
| Caspase 3 | 2 | 2022 | 97 | 0.120 |
Why?
| Serum | 1 | 2014 | 32 | 0.120 |
Why?
| Cell Lineage | 1 | 2014 | 83 | 0.120 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2014 | 36 | 0.120 |
Why?
| Superoxide Dismutase | 1 | 2014 | 113 | 0.120 |
Why?
| Translocation, Genetic | 4 | 2021 | 264 | 0.120 |
Why?
| Tumor Burden | 3 | 2020 | 132 | 0.120 |
Why?
| Piperidines | 1 | 2015 | 98 | 0.120 |
Why?
| Cyclins | 3 | 2015 | 38 | 0.120 |
Why?
| HLA Antigens | 1 | 2014 | 52 | 0.120 |
Why?
| Alkaline Phosphatase | 2 | 2011 | 94 | 0.120 |
Why?
| Glycoproteins | 1 | 2014 | 115 | 0.120 |
Why?
| Repressor Proteins | 4 | 2015 | 151 | 0.110 |
Why?
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2013 | 12 | 0.110 |
Why?
| Leukemia, Plasma Cell | 1 | 2013 | 33 | 0.110 |
Why?
| Lactate Dehydrogenases | 1 | 2013 | 1 | 0.110 |
Why?
| Phenotype | 4 | 2009 | 729 | 0.110 |
Why?
| Genome, Human | 2 | 2021 | 111 | 0.110 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 63 | 0.110 |
Why?
| Follow-Up Studies | 5 | 2024 | 2182 | 0.110 |
Why?
| Scavenger Receptors, Class A | 1 | 2013 | 39 | 0.110 |
Why?
| bcl-X Protein | 1 | 2013 | 50 | 0.110 |
Why?
| Leukemia | 1 | 2013 | 65 | 0.110 |
Why?
| Dose-Response Relationship, Drug | 4 | 2020 | 1376 | 0.110 |
Why?
| Disease Models, Animal | 4 | 2020 | 1455 | 0.110 |
Why?
| Heat-Shock Proteins | 1 | 2013 | 106 | 0.100 |
Why?
| RNA, Neoplasm | 3 | 2007 | 44 | 0.100 |
Why?
| Clinical Trials, Phase III as Topic | 2 | 2012 | 43 | 0.100 |
Why?
| RNA, Small Interfering | 2 | 2010 | 215 | 0.100 |
Why?
| Forkhead Transcription Factors | 2 | 2023 | 112 | 0.100 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2011 | 22 | 0.100 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2020 | 136 | 0.100 |
Why?
| Activated Protein C Resistance | 1 | 2011 | 10 | 0.100 |
Why?
| Factor V | 1 | 2011 | 11 | 0.100 |
Why?
| Protein Isoforms | 2 | 2009 | 119 | 0.100 |
Why?
| Glucocorticoids | 1 | 2013 | 219 | 0.100 |
Why?
| Acetylcysteine | 1 | 2011 | 100 | 0.100 |
Why?
| Interferon Regulatory Factor-1 | 1 | 2010 | 14 | 0.090 |
Why?
| Cell Growth Processes | 1 | 2010 | 22 | 0.090 |
Why?
| HLA-A Antigens | 2 | 2007 | 10 | 0.090 |
Why?
| Alleles | 2 | 2021 | 250 | 0.090 |
Why?
| Gene Silencing | 2 | 2007 | 119 | 0.090 |
Why?
| Cells, Cultured | 6 | 2015 | 1573 | 0.090 |
Why?
| Epigenesis, Genetic | 2 | 2023 | 374 | 0.090 |
Why?
| Immunophenotyping | 5 | 2010 | 109 | 0.090 |
Why?
| Thrombosis | 1 | 2012 | 248 | 0.090 |
Why?
| K562 Cells | 3 | 2016 | 42 | 0.090 |
Why?
| Microtubule-Associated Proteins | 1 | 2009 | 67 | 0.080 |
Why?
| Bone Remodeling | 1 | 2010 | 150 | 0.080 |
Why?
| Recombinant Proteins | 1 | 2010 | 486 | 0.080 |
Why?
| Chromosome Mapping | 2 | 2006 | 156 | 0.080 |
Why?
| Thromboembolism | 1 | 2009 | 54 | 0.080 |
Why?
| Neoplasm Staging | 3 | 2024 | 740 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 13 | 0.080 |
Why?
| Mutation | 3 | 2021 | 1294 | 0.080 |
Why?
| Receptors, Immunologic | 1 | 2008 | 37 | 0.080 |
Why?
| ras Proteins | 2 | 2020 | 64 | 0.080 |
Why?
| Neoplasm Transplantation | 2 | 2020 | 85 | 0.080 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 7 | 0.080 |
Why?
| Angiogenesis Inhibitors | 1 | 2009 | 187 | 0.080 |
Why?
| Patient Selection | 1 | 2009 | 253 | 0.080 |
Why?
| Genes, abl | 1 | 2007 | 2 | 0.080 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2007 | 24 | 0.080 |
Why?
| Adoptive Transfer | 1 | 2007 | 40 | 0.080 |
Why?
| Breast Neoplasms | 2 | 2007 | 1174 | 0.070 |
Why?
| Gene Expression Regulation | 2 | 2022 | 976 | 0.070 |
Why?
| HEK293 Cells | 2 | 2019 | 222 | 0.070 |
Why?
| Cancer Vaccines | 1 | 2007 | 78 | 0.070 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2007 | 72 | 0.070 |
Why?
| Drug Evaluation, Preclinical | 2 | 2021 | 144 | 0.070 |
Why?
| Caspases | 1 | 2007 | 104 | 0.070 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.070 |
Why?
| Chromosome Banding | 1 | 2006 | 24 | 0.070 |
Why?
| Proportional Hazards Models | 2 | 2024 | 402 | 0.070 |
Why?
| Models, Genetic | 1 | 2006 | 170 | 0.070 |
Why?
| Palatine Tonsil | 2 | 2003 | 11 | 0.070 |
Why?
| Peptides | 1 | 2007 | 223 | 0.070 |
Why?
| DNA Damage | 1 | 2008 | 301 | 0.070 |
Why?
| Maf Transcription Factors, Large | 1 | 2005 | 1 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 181 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2006 | 158 | 0.060 |
Why?
| Doxorubicin | 2 | 2018 | 233 | 0.060 |
Why?
| Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| Cyclin D1 | 1 | 2005 | 56 | 0.060 |
Why?
| Antibody Formation | 1 | 2005 | 54 | 0.060 |
Why?
| Protein Biosynthesis | 2 | 2003 | 253 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 1816 | 0.060 |
Why?
| Cystadenocarcinoma, Serous | 1 | 2004 | 70 | 0.060 |
Why?
| Papillomaviridae | 1 | 2005 | 102 | 0.060 |
Why?
| Carcinoma, Papillary | 1 | 2004 | 48 | 0.060 |
Why?
| Base Sequence | 3 | 2015 | 643 | 0.060 |
Why?
| Transfection | 2 | 2020 | 354 | 0.060 |
Why?
| Transcription, Genetic | 1 | 2005 | 369 | 0.060 |
Why?
| Mice, Inbred BALB C | 2 | 2019 | 304 | 0.060 |
Why?
| Drug Synergism | 2 | 2014 | 150 | 0.060 |
Why?
| Jurkat Cells | 2 | 2014 | 29 | 0.060 |
Why?
| Zebrafish Proteins | 1 | 2003 | 21 | 0.060 |
Why?
| Extracellular Matrix Proteins | 1 | 2004 | 69 | 0.060 |
Why?
| Genetic Predisposition to Disease | 1 | 2007 | 510 | 0.060 |
Why?
| Adipogenesis | 1 | 2024 | 51 | 0.060 |
Why?
| Steroids | 1 | 2024 | 57 | 0.060 |
Why?
| Ovariectomy | 1 | 2024 | 119 | 0.060 |
Why?
| Sequence Analysis, RNA | 1 | 2024 | 91 | 0.060 |
Why?
| PPAR gamma | 1 | 2024 | 73 | 0.060 |
Why?
| Integrin beta Chains | 1 | 2023 | 14 | 0.050 |
Why?
| Integrins | 1 | 2023 | 31 | 0.050 |
Why?
| Oxidative Phosphorylation | 1 | 2023 | 39 | 0.050 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2003 | 38 | 0.050 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.050 |
Why?
| Cytogenetic Analysis | 1 | 2023 | 82 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2002 | 31 | 0.050 |
Why?
| Chromosomes, Human, Pair 14 | 1 | 2002 | 75 | 0.050 |
Why?
| Oncogene Proteins, Fusion | 1 | 2002 | 58 | 0.050 |
Why?
| Macrophage Activation | 1 | 2022 | 25 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2023 | 140 | 0.050 |
Why?
| Porphyromonas gingivalis | 1 | 2022 | 16 | 0.050 |
Why?
| Computational Biology | 2 | 2020 | 214 | 0.050 |
Why?
| Geography | 1 | 2022 | 61 | 0.050 |
Why?
| Protein Kinase Inhibitors | 2 | 2014 | 204 | 0.050 |
Why?
| Chromatin | 1 | 2023 | 151 | 0.050 |
Why?
| Uterine Cervical Neoplasms | 1 | 2005 | 277 | 0.050 |
Why?
| Inflammasomes | 1 | 2022 | 58 | 0.050 |
Why?
| Diploidy | 3 | 2007 | 26 | 0.050 |
Why?
| DNA, Neoplasm | 1 | 2002 | 147 | 0.050 |
Why?
| Models, Animal | 2 | 2015 | 233 | 0.050 |
Why?
| Mutation Rate | 1 | 2021 | 36 | 0.050 |
Why?
| DNA Primers | 2 | 2015 | 207 | 0.050 |
Why?
| Clone Cells | 1 | 2021 | 74 | 0.050 |
Why?
| Proteins | 1 | 2003 | 342 | 0.050 |
Why?
| Genes, Tumor Suppressor | 1 | 2021 | 73 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 66 | 0.050 |
Why?
| HCT116 Cells | 1 | 2020 | 22 | 0.050 |
Why?
| DNA Copy Number Variations | 1 | 2021 | 110 | 0.050 |
Why?
| Ovarian Neoplasms | 1 | 2004 | 447 | 0.050 |
Why?
| Double-Blind Method | 2 | 2014 | 681 | 0.040 |
Why?
| Cytokines | 3 | 2009 | 612 | 0.040 |
Why?
| Wnt Signaling Pathway | 1 | 2021 | 92 | 0.040 |
Why?
| 3' Untranslated Regions | 1 | 2020 | 52 | 0.040 |
Why?
| Immunohistochemistry | 3 | 2009 | 973 | 0.040 |
Why?
| Gene Knockout Techniques | 1 | 2019 | 40 | 0.040 |
Why?
| Software | 1 | 2002 | 273 | 0.040 |
Why?
| Drug Discovery | 1 | 2020 | 85 | 0.040 |
Why?
| DNA | 1 | 2023 | 541 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 213 | 0.040 |
Why?
| Crystallography, X-Ray | 1 | 2019 | 147 | 0.040 |
Why?
| Protein Phosphatase 2 | 1 | 2019 | 5 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 169 | 0.040 |
Why?
| G1 Phase | 1 | 2019 | 14 | 0.040 |
Why?
| Enzyme Activators | 1 | 2019 | 8 | 0.040 |
Why?
| Protein Conformation | 1 | 2019 | 166 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2021 | 577 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 252 | 0.040 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.040 |
Why?
| Immunotherapy | 1 | 2021 | 238 | 0.040 |
Why?
| Structure-Activity Relationship | 1 | 2020 | 395 | 0.040 |
Why?
| Wnt Proteins | 2 | 2013 | 100 | 0.040 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2019 | 77 | 0.040 |
Why?
| Drug Resistance | 1 | 2018 | 63 | 0.040 |
Why?
| Phosphorylation | 1 | 2020 | 535 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 548 | 0.040 |
Why?
| Autophagy | 1 | 2020 | 169 | 0.040 |
Why?
| Cross-Sectional Studies | 1 | 2022 | 1557 | 0.040 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 32 | 0.040 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2007 | 116 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2016 | 82 | 0.030 |
Why?
| Chronic Disease | 1 | 2019 | 567 | 0.030 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2016 | 43 | 0.030 |
Why?
| Biological Transport | 1 | 2016 | 174 | 0.030 |
Why?
| Models, Statistical | 2 | 2008 | 224 | 0.030 |
Why?
| Drug Interactions | 1 | 2016 | 206 | 0.030 |
Why?
| Mice, Inbred ICR | 1 | 2016 | 22 | 0.030 |
Why?
| Cell Line | 2 | 2013 | 1000 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2015 | 75 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2016 | 121 | 0.030 |
Why?
| Vidarabine | 1 | 2015 | 9 | 0.030 |
Why?
| Mitoxantrone | 1 | 2015 | 9 | 0.030 |
Why?
| Reoviridae | 1 | 2015 | 25 | 0.030 |
Why?
| Pharmacogenetics | 2 | 2006 | 52 | 0.030 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 47 | 0.030 |
Why?
| Vaccination | 2 | 2007 | 266 | 0.030 |
Why?
| China | 1 | 2015 | 87 | 0.030 |
Why?
| Vincristine | 1 | 2015 | 89 | 0.030 |
Why?
| Prednisone | 1 | 2015 | 99 | 0.030 |
Why?
| Ligands | 1 | 2015 | 204 | 0.030 |
Why?
| Molecular Targeted Therapy | 1 | 2016 | 119 | 0.030 |
Why?
| Disulfiram | 1 | 2014 | 10 | 0.030 |
Why?
| Glutathione Peroxidase | 1 | 2014 | 23 | 0.030 |
Why?
| Cyclin B | 1 | 2014 | 4 | 0.030 |
Why?
| Microscopy, Fluorescence | 1 | 2015 | 162 | 0.030 |
Why?
| CDC2 Protein Kinase | 1 | 2014 | 16 | 0.030 |
Why?
| Portraits as Topic | 1 | 2014 | 2 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2015 | 165 | 0.030 |
Why?
| Risk Assessment | 2 | 2009 | 1259 | 0.030 |
Why?
| Glucose | 1 | 2016 | 344 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 38 | 0.030 |
Why?
| Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 11 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2014 | 119 | 0.030 |
Why?
| Lectins, C-Type | 1 | 2013 | 30 | 0.030 |
Why?
| Veratrum Alkaloids | 1 | 2013 | 5 | 0.030 |
Why?
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 17 | 0.030 |
Why?
| Isoxazoles | 1 | 2013 | 14 | 0.030 |
Why?
| G1 Phase Cell Cycle Checkpoints | 1 | 2013 | 17 | 0.030 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2013 | 33 | 0.030 |
Why?
| Glutathione | 1 | 2014 | 295 | 0.030 |
Why?
| Hedgehog Proteins | 1 | 2013 | 33 | 0.030 |
Why?
| Sulfones | 1 | 2013 | 24 | 0.030 |
Why?
| Itraconazole | 1 | 2013 | 40 | 0.030 |
Why?
| Peptide Library | 1 | 2013 | 16 | 0.030 |
Why?
| Receptors, Glucocorticoid | 1 | 2013 | 32 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 22 | 0.030 |
Why?
| Azacitidine | 1 | 2013 | 34 | 0.030 |
Why?
| Oxidants | 1 | 2013 | 53 | 0.030 |
Why?
| ADP-ribosyl Cyclase | 2 | 2003 | 5 | 0.030 |
Why?
| Epitopes | 1 | 2013 | 59 | 0.030 |
Why?
| Hydrocortisone | 1 | 2013 | 107 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2013 | 96 | 0.030 |
Why?
| MAP Kinase Signaling System | 1 | 2013 | 119 | 0.030 |
Why?
| Prospective Studies | 2 | 2010 | 2364 | 0.030 |
Why?
| Histone Deacetylases | 1 | 2013 | 50 | 0.030 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 115 | 0.030 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 129 | 0.030 |
Why?
| Radiation, Ionizing | 1 | 2013 | 100 | 0.030 |
Why?
| Osteoblasts | 2 | 2006 | 450 | 0.030 |
Why?
| Transcriptome | 1 | 2014 | 315 | 0.030 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2012 | 43 | 0.030 |
Why?
| Viper Venoms | 1 | 2011 | 7 | 0.020 |
Why?
| Protein C | 1 | 2011 | 18 | 0.020 |
Why?
| Risk | 1 | 2011 | 320 | 0.020 |
Why?
| Bone Density Conservation Agents | 1 | 2010 | 77 | 0.020 |
Why?
| Diphosphonates | 1 | 2010 | 90 | 0.020 |
Why?
| Databases as Topic | 1 | 2009 | 37 | 0.020 |
Why?
| Parathyroid Hormone | 1 | 2010 | 147 | 0.020 |
Why?
| Lymphocytes | 1 | 2010 | 152 | 0.020 |
Why?
| Cytoskeleton | 1 | 2008 | 39 | 0.020 |
Why?
| Genotype | 1 | 2009 | 537 | 0.020 |
Why?
| Twins | 1 | 2007 | 33 | 0.020 |
Why?
| STAT Transcription Factors | 1 | 2007 | 8 | 0.020 |
Why?
| Cytological Techniques | 1 | 2007 | 14 | 0.020 |
Why?
| NF-kappa B p52 Subunit | 1 | 2007 | 6 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 225 | 0.020 |
Why?
| NF-kappa B p50 Subunit | 1 | 2007 | 17 | 0.020 |
Why?
| I-kappa B Kinase | 1 | 2007 | 20 | 0.020 |
Why?
| Karyotyping | 1 | 2007 | 83 | 0.020 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 65 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
| Antigen Presentation | 1 | 2007 | 25 | 0.020 |
Why?
| Benzamides | 1 | 2007 | 51 | 0.020 |
Why?
| Remission Induction | 1 | 2007 | 207 | 0.020 |
Why?
| Polysaccharide-Lyases | 1 | 2007 | 6 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 116 | 0.020 |
Why?
| Plasmids | 1 | 2007 | 161 | 0.020 |
Why?
| Tissue Culture Techniques | 1 | 2007 | 40 | 0.020 |
Why?
| Interferon-gamma | 1 | 2007 | 177 | 0.020 |
Why?
| Enzyme Activation | 1 | 2007 | 276 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 244 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 56 | 0.020 |
Why?
| Anticoagulants | 1 | 2009 | 250 | 0.020 |
Why?
| Piperazines | 1 | 2007 | 117 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2006 | 47 | 0.020 |
Why?
| Neoplasms, Experimental | 1 | 2007 | 114 | 0.020 |
Why?
| Dendritic Cells | 1 | 2007 | 133 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1037 | 0.020 |
Why?
| Incidence | 1 | 2009 | 1003 | 0.020 |
Why?
| Receptors, Estrogen | 1 | 2007 | 130 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2007 | 453 | 0.020 |
Why?
| Chromosomes, Human | 1 | 2006 | 41 | 0.020 |
Why?
| Gelatinases | 1 | 2006 | 32 | 0.020 |
Why?
| Rabbits | 1 | 2006 | 370 | 0.020 |
Why?
| Endopeptidases | 1 | 2006 | 66 | 0.020 |
Why?
| Coculture Techniques | 1 | 2006 | 146 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2007 | 637 | 0.020 |
Why?
| Cyclin D3 | 1 | 2005 | 5 | 0.020 |
Why?
| Cyclin D2 | 1 | 2005 | 20 | 0.020 |
Why?
| Trisomy | 1 | 2005 | 31 | 0.020 |
Why?
| Adipocytes | 1 | 2006 | 121 | 0.020 |
Why?
| Oligonucleotide Probes | 1 | 2004 | 20 | 0.020 |
Why?
| Stem Cells | 1 | 2006 | 171 | 0.020 |
Why?
| Epithelium | 1 | 2004 | 65 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2006 | 792 | 0.020 |
Why?
| Endothelium, Vascular | 1 | 2006 | 252 | 0.010 |
Why?
| Ovary | 1 | 2004 | 104 | 0.010 |
Why?
| Endothelial Cells | 1 | 2006 | 269 | 0.010 |
Why?
| Databases, Factual | 1 | 2007 | 658 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 376 | 0.010 |
Why?
| RNA, Complementary | 1 | 2003 | 3 | 0.010 |
Why?
| Autocrine Communication | 1 | 2003 | 8 | 0.010 |
Why?
| Paracrine Communication | 1 | 2003 | 12 | 0.010 |
Why?
| Metaphase | 1 | 2003 | 44 | 0.010 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2002 | 18 | 0.010 |
Why?
| Cell Separation | 1 | 2003 | 89 | 0.010 |
Why?
| Melanoma-Specific Antigens | 1 | 2002 | 3 | 0.010 |
Why?
| NAD+ Nucleosidase | 1 | 2002 | 3 | 0.010 |
Why?
| Biopsy | 1 | 2005 | 584 | 0.010 |
Why?
| Cell Communication | 1 | 2003 | 69 | 0.010 |
Why?
| Antigens, Differentiation | 1 | 2002 | 17 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2003 | 138 | 0.010 |
Why?
| Cohort Studies | 1 | 2006 | 1422 | 0.010 |
Why?
| Immunoglobulins | 1 | 2002 | 79 | 0.010 |
Why?
| Database Management Systems | 1 | 2002 | 28 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2005 | 1193 | 0.010 |
Why?
| Logistic Models | 1 | 2003 | 888 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2003 | 1537 | 0.010 |
Why?
|
|
Zhan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|